APO
Desconocido
MEL-PLEX: Exploiting MELanoma disease comPLEXity to address European research training needs in translational...
APOGENIX GMBH
participó en un
H2020:
H2020-MSCA-ITN-2014
Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous a...
2014-12-16 - 2018-11-30 | Financiado
2014-12-16 - 2018-11-30 | Financiado
TARGETBINDER: Target binders
APOGENIX GMBH
participó en un
FP7:
We want to further develop our tools and technologies for high-throughput research, with the final goals being (I.) the particle-based combi...
Financiado
Financiado
* No se disponen de datos de la empresa actual.